Research & Development

Publications

Advancing Understanding Through Collaborative Research

1

CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms
Greenman et al., Cells. 2025; 14(2):105

2

Machine learning identifies key proteins in primary sclerosing cholangitis progression and links high CCL24 to cirrhosis
Snir et al., Int. J. Mol. Sci. 2024, 25, 6042

3

Targeting CCL24 in inflammatory and fibrotic diseases: rationale and results from three CM-101 Phase 1 studies
Mor, et al., Drug Safety, June 2024

4

Serum CCL24 as a biomarker of fibrotic and vascular disease severity in systemic sclerosis
De Lorenzis, et al., Arthritis Care & Research, April 2024

5

The role of CCL24 in primary sclerosing cholangitis: bridging patient serum proteomics to preclinical data
Greenman, R.; et al. The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data. Cells 2024, 13, 209

6

CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis
Mor et al. JCI Insight. 2023: 8(12): e162270

7

The role of CCL24 in systemic sclerosis
Levy H, et al. The Role of CCL24 in Systemic Sclerosis. Rambam Maimonides Med J 2023;14 (3):e0016

8

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage
Segal-Salto et al. JHEP Rep. 2020 Jan 2;2(1):100064

9

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients
Furer et al., Pain Res Manag. 2018: 7257681

10

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
Mor et al. Ann Rheum Dis 2019;78:1260–1268

11

Eotaxin-2 blockade ameliorates experimental autoimmune encephalomyelitis
Mausner-Fainberg et al. World J. Immunol. 2013 Mar; 3(1):7-14.

12

Anti eotaxin-2 antibodies attenuate the initiation and progression of experimental atherosclerosis
Mor et al. World J. Cardiovascular Dis. 2013; 3:339-346

13

Protective effect of eotaxin-2 inhibition in adjuvant-induced arthritis
Ablin et al. Clinical and Experimental Immunology. 2010; V161(2):276–83